Related Experiment Videos
Clinical study on cardiac sarcoidosis
Insights
Cardiac sarcoidosis can cause focal left ventricular perfusion defects, which may resolve over time. However, persistent defects and reduced ejection fraction indicate a poorer prognosis, especially in fatal cases.
Area of Science:
- Cardiology
- Immunology
- Pathology
Background:
- Sarcoidosis is a multisystem inflammatory disease.
- Cardiac involvement in sarcoidosis can lead to significant morbidity and mortality.
- Early detection and monitoring of cardiac sarcoidosis are crucial.
Purpose of the Study:
- To investigate cardiac involvement in patients with sarcoidosis.
- To assess the prognostic significance of left ventricular perfusion defects.
- To correlate imaging findings with electrocardiographic abnormalities and serological markers.
Main Methods:
- Investigated 41 patients with sarcoidosis for cardiac involvement.
- Utilized Thallium-201 Myocardial Perfusion Scintigraphy (TMPS) to assess perfusion defects.
- Performed echocardiography and Holter ECG monitoring.
- Measured Serum Angiotensin-Converting Enzyme (SACE) activity.
Main Results:
- Focal left ventricular perfusion defects were identified in 5 of 41 patients.
- Defects resolved in 4 patients over 3 years, but persisted in a fatal case.
- Reduced left ventricular ejection fraction was observed in 14 patients.
- Echocardiography showed wall dysfunction only in the fatal case.
- Holter ECG revealed abnormalities in 13 of 32 patients.
- Elevated SACE activity correlated with perfusion defects in some patients.
Conclusions:
- Left ventricular perfusion defects in cardiac sarcoidosis can be dynamic.
- Persistent defects and reduced ejection fraction are associated with poor outcomes.
- SACE activity may serve as a biomarker for cardiac sarcoidosis activity.
Abstract:
Forty-one patients with sarcoidosis were investigated for cardiac involvement. The results are summarized as follows: The focal left ventricular perfusion defect was found on the TMPS's of 5 out of 41 patients with sarcoidosis. The defect disappeared in four of these five patients over a 3-year period, but remained in the patient with fatal myocardial sarcoidosis. A decreased left ventricular ejection fraction was found in 14 out of 41 patients with sarcoidosis, and in 3 out of 5 patients with the left ventricular perfusion defect. Echocardiographic examination did not reveal left ventricular wall dysfunction at the site of the left ventricular perfusion defect, except in one patient with fatal myocardial sarcoidosis. Holter ECG's showed such abnormalities as CRBBB, heart blocks, PVC, and PSC in 13 out of 32 patients with sarcoidosis. SACE activity was elevated in all three patients with the left ventricular perfusion defect that were examined, and it could be correlated with changes in the left ventricular perfusion defect in one of them.